vs
OptimumBank Holdings, Inc.（OPHC）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
OptimumBank Holdings, Inc.的季度营收约是Protalix BioTherapeutics, Inc.的1.5倍（$13.6M vs $9.1M），OptimumBank Holdings, Inc.净利率更高（35.7% vs -60.3%，领先96.0%），OptimumBank Holdings, Inc.同比增速更快（32.0% vs -49.9%），OptimumBank Holdings, Inc.自由现金流更多（$16.9M vs $1.6M），过去两年OptimumBank Holdings, Inc.的营收复合增速更高（23.0% vs -6.7%）
OptimumBank Holdings, Inc.是总部位于美国佛罗里达州的银行控股企业，旗下运营社区银行OptimumBank，面向佛罗里达州南部的个人消费者与中小企业，提供存款、各类贷款、财富管理等综合银行服务。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
OPHC vs PLX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.6M | $9.1M |
| 净利润 | $4.9M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | 47.5% | -51.1% |
| 净利率 | 35.7% | -60.3% |
| 营收同比 | 32.0% | -49.9% |
| 净利润同比 | 22.9% | -184.8% |
| 每股收益（稀释后） | $-0.08 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $13.6M | $9.1M | ||
| Q3 25 | $13.0M | $17.9M | ||
| Q2 25 | $12.1M | $15.7M | ||
| Q1 25 | $10.7M | $10.1M | ||
| Q4 24 | $10.3M | $18.2M | ||
| Q3 24 | $10.1M | $18.0M | ||
| Q2 24 | $9.9M | $13.5M | ||
| Q1 24 | $9.0M | — |
| Q4 25 | $4.9M | $-5.5M | ||
| Q3 25 | $4.3M | $2.4M | ||
| Q2 25 | $3.6M | $164.0K | ||
| Q1 25 | $3.9M | $-3.6M | ||
| Q4 24 | $3.9M | $6.5M | ||
| Q3 24 | $3.3M | $3.2M | ||
| Q2 24 | $3.5M | $-2.2M | ||
| Q1 24 | $2.4M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | 47.5% | -51.1% | ||
| Q3 25 | 43.5% | 11.9% | ||
| Q2 25 | 40.2% | 7.5% | ||
| Q1 25 | 48.8% | -41.0% | ||
| Q4 24 | 51.5% | 39.6% | ||
| Q3 24 | 44.0% | 22.2% | ||
| Q2 24 | 46.9% | -18.0% | ||
| Q1 24 | 35.9% | — |
| Q4 25 | 35.7% | -60.3% | ||
| Q3 25 | 33.2% | 13.2% | ||
| Q2 25 | 29.8% | 1.0% | ||
| Q1 25 | 36.3% | -35.8% | ||
| Q4 24 | 38.3% | 35.6% | ||
| Q3 24 | 32.8% | 18.0% | ||
| Q2 24 | 35.2% | -16.4% | ||
| Q1 24 | 26.4% | — |
| Q4 25 | $-0.08 | $-0.06 | ||
| Q3 25 | $0.18 | $0.03 | ||
| Q2 25 | $0.29 | $0.00 | ||
| Q1 25 | $0.32 | $-0.05 | ||
| Q4 24 | $-0.17 | $0.10 | ||
| Q3 24 | $0.15 | $0.03 | ||
| Q2 24 | $0.34 | $-0.03 | ||
| Q1 24 | $0.31 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $121.9M | $48.2M |
| 总资产 | $1.1B | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | — |
| Q4 25 | $121.9M | $48.2M | ||
| Q3 25 | $116.9M | $52.9M | ||
| Q2 25 | $111.3M | $49.9M | ||
| Q1 25 | $108.0M | $45.2M | ||
| Q4 24 | $103.2M | $43.2M | ||
| Q3 24 | $92.7M | $32.4M | ||
| Q2 24 | $87.0M | $28.6M | ||
| Q1 24 | $83.0M | — |
| Q4 25 | $1.1B | $82.3M | ||
| Q3 25 | $1.1B | $82.3M | ||
| Q2 25 | $999.1M | $78.5M | ||
| Q1 25 | $977.5M | $73.9M | ||
| Q4 24 | $932.9M | $73.4M | ||
| Q3 24 | $945.2M | $61.6M | ||
| Q2 24 | $899.8M | $91.5M | ||
| Q1 24 | $940.6M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.8M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $16.9M | $1.6M |
| 自由现金流率自由现金流/营收 | 124.6% | 17.8% |
| 资本支出强度资本支出/营收 | 6.6% | 4.4% |
| 现金转化率经营现金流/净利润 | 3.68× | — |
| 过去12个月自由现金流最近4个季度 | $27.6M | $-13.6M |
8季度趋势，按日历期对齐
| Q4 25 | $17.8M | $2.0M | ||
| Q3 25 | $1.9M | $-3.7M | ||
| Q2 25 | $6.2M | $-5.2M | ||
| Q1 25 | $3.1M | $-5.1M | ||
| Q4 24 | $15.6M | $4.0M | ||
| Q3 24 | $4.0M | $4.1M | ||
| Q2 24 | $3.1M | $-3.6M | ||
| Q1 24 | $2.5M | — |
| Q4 25 | $16.9M | $1.6M | ||
| Q3 25 | $1.9M | $-4.2M | ||
| Q2 25 | $5.9M | $-5.7M | ||
| Q1 25 | $2.9M | $-5.4M | ||
| Q4 24 | $14.6M | $3.6M | ||
| Q3 24 | $3.9M | $4.0M | ||
| Q2 24 | $2.7M | $-3.8M | ||
| Q1 24 | $2.3M | — |
| Q4 25 | 124.6% | 17.8% | ||
| Q3 25 | 14.7% | -23.7% | ||
| Q2 25 | 48.5% | -36.2% | ||
| Q1 25 | 26.8% | -53.0% | ||
| Q4 24 | 141.9% | 19.6% | ||
| Q3 24 | 38.3% | 22.4% | ||
| Q2 24 | 27.5% | -28.1% | ||
| Q1 24 | 25.4% | — |
| Q4 25 | 6.6% | 4.4% | ||
| Q3 25 | 0.0% | 2.8% | ||
| Q2 25 | 2.5% | 2.8% | ||
| Q1 25 | 2.7% | 3.0% | ||
| Q4 24 | 9.6% | 2.3% | ||
| Q3 24 | 1.5% | 0.5% | ||
| Q2 24 | 3.6% | 1.3% | ||
| Q1 24 | 2.9% | — |
| Q4 25 | 3.68× | — | ||
| Q3 25 | 0.44× | -1.58× | ||
| Q2 25 | 1.71× | -31.91× | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 3.95× | 0.61× | ||
| Q3 24 | 1.21× | 1.27× | ||
| Q2 24 | 0.89× | — | ||
| Q1 24 | 1.07× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OPHC
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
